Havemeyer Place LP Makes New $1.10 Million Investment in Becton, Dickinson and Company $BDX

Havemeyer Place LP purchased a new position in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,657 shares of the medical instruments supplier’s stock, valued at approximately $1,098,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Crux Wealth Advisors boosted its stake in Becton, Dickinson and Company by 0.8% in the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock worth $1,222,000 after purchasing an additional 49 shares during the period. Larson Financial Group LLC boosted its stake in Becton, Dickinson and Company by 1.7% in the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 53 shares during the period. Camelot Portfolios LLC boosted its stake in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC boosted its stake in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp boosted its stake in Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after purchasing an additional 57 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 2,913 shares of company stock worth $426,806. Corporate insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of several recent analyst reports. Evercore upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Weiss Ratings downgraded Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Citigroup dropped their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a report on Tuesday, April 14th. Finally, The Goldman Sachs Group decreased their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $183.64.

Becton, Dickinson and Company Stock Up 0.1%

Shares of BDX opened at $151.33 on Monday. The stock has a market capitalization of $41.70 billion, a price-to-earnings ratio of 38.31, a price-to-earnings-growth ratio of 10.70 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The business’s 50 day simple moving average is $150.72 and its 200-day simple moving average is $175.43. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.